TABLE 1.
Demographic and Clinical Characteristics of Individuals Who Were and Were Not Prescribed Gabapentin in 2016
| Individuals Prescribed Gabapentin, n (%) (n = 536,488) | Individuals Not Prescribed Gabapentin, n (%) (n = 19,266,873) | |
|---|---|---|
| Region (N = 19,803,361) | ||
| Northeast | 66,625 (12.4) | 3,131,730 (16.3) |
| Midwest | 106,604 (19.9) | 3,753,529 (19.5) |
| South | 287,910 (53.7) | 9,055,912 (47.0) |
| West | 75,349 (14.0) | 3,325,702 (17.3) |
| Sex | ||
| Male | 201,077 (37.5) | 9,190,284 (47.7) |
| Female | 335,411 (62.5) | 10,076,589 (52.3) |
| Age group, years | ||
| 18-34 | 61,652 (11.5) | 7,030,865 (36.5) |
| 35-44 | 88,285 (16.5) | 3,910,073 (20.3) |
| 45-54 | 162,911 (30.4) | 4,247,578 (22.0) |
| 55-64 | 223,640 (41.7) | 4,078,357 (21.2) |
| Opioid use | ||
| Yes | 326,098 (60.8) | 3,187,077 (16.5) |
| No | 210,390 (39.2) | 16,079,796 (83.5) |
| Mean number prescriptions | 6.48 (7.0) | 2.65 (4.0) |
| Mean days supply | 15.81 (11.8) | 8.15 (9.2) |
| Comorbidities, rates per 1,000 | ||
| Seizure disorders | 25.9 | 6.3 |
| Neuropathic pain | 506.6 | 80.1 |
| Mental health disorders | 395.4 | 144.7 |
| Substance use disorder | 162.8 | 37.3 |
| Diabetes | 303.9 | 101.1 |
Note: All differences between individuals who were and were not prescribed gabapentin were significantly different at the P < 0.0001 level using chi-square tests and t-tests where appropriate.